Global leader in molecular glue degrader medicines
Degron Therapeutics is a clinical-stage biotech developing molecular glue degrader drugs targeting previously undruggable proteins in oncology, inflammation, and metabolic disease. Founded in 2021, the company has advanced its lead asset DEG6498, a first-in-class HuR-targeting MGD, into Phase 1 clinical trials. Headquartered in San Diego with operations in Shanghai.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2026
Jun 2022
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
